Richard Maziarz, MD
Enriched profileProfessor of Medicine; Medical Director, Adult Blood & Marrow Transplantation and Immune Effector Cell Therapy Programs · Oregon Health & Science University
Richard Maziarz is Professor of Medicine; Medical Director, Adult Blood & Marrow Transplantation and Immune Effector Cell Therapy Programs at Oregon Health & Science University. OpenAlex indexes 720 publications with 32,932 citations (h-index 86); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Richard Maziarz, MD, is Professor of Medicine at Oregon Health & Science University, School of Medicine, Knight Cancer Institute. The public record shows 720 publications with 32,932 citations (h-index 86), centered on Hematopoietic Stem Cell Transplantation, CAR-T cell therapy research, Acute Myeloid Leukemia Research. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 16 companies, 2 NIH-funded awards (2017–2026).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Hematopoietic Stem Cell Transplantation
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 297.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- Chair
Committee on Drug Shortages, US HHS Health Resources and Services Administration Advisory Council
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor: Allogene Therapeutics
- GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Sponsor: Eureka Therapeutics Inc.
Industry payments
Updated 14 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20257 payments
- bioMerieux IncProgram year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
30.7%Short-acting sulfonamides14.5%Sulfamethoxazole-Trimethoprim100%Part D≥11 patientsFluoroquinolone Antibacterial5.7%Levofloxacin100%Part D≥11 patients+ 2 more classes in this area
Dermatology
25.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor25.4%Acyclovir100%Part D≥21 patientsMetabolism & gastrointestinal
15.4%Corticosteroid8.3%Prednisone100%Part D<11 patientsSerotonin-3 Receptor Antagonist7%Ondansetron Odt100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- BMT Core - Oregon Health and Science University (OHSU) Consortium
Oregon Health & Science University
FY2026$228,000UG1HL174405 - BMT Core - Oregon Health and Science University (OHSU) Consortium
Oregon Health & Science University
FY2025$228,000UG1HL174405 - BMT Core - Oregon Health and Science University (OHSU) Consortium
Oregon Health & Science University
FY2024$244,000UG1HL174405
Congress activity
Updated 14 Oct 2026
79 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Journal of clinical oncology
Clinical Trial2026 - Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.
Blood cancer discovery
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/richard-maziarz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Richard-T-Maziarz-39481286
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
thebloodline.org/212e212
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thebloodline.org ↗ - LinkedIn
LinkedIn profile listing title "Medical Director, Blood & Marrow Transplant and Cellular Therapy Program"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- Research/clinical fellowship in Hematology
Brigham and Women's Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗ - Clinical fellowship in Medical Oncology
Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Editorial & leadership roles
journal and society appointments- Founding Director
OHSU Immunotherapy and Cell Transplant Therapy Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Associate Editor
Transplantation & Cellular Therapy (journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗ - Editorial Board
Cytotherapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗ - Editorial Board
Bone Marrow Transplantation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Secondary affiliations
appointments beyond the home institution- Steering Committee member
BMT CTN (Blood and Marrow Transplant Clinical Trials Network)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Chair
Regimen Related Toxicity Strategic Planning Committee, BMT CTN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Chair
Scientific Steering Committee, Juliet trial
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Chair
Health Economics SIG, American Society for Transplantation and Cellular Therapy (ASTCT)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Vice President
Executive Committee, American Society for Transplantation and Cellular Therapy (ASTCT)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Member
CIBMTR Health Policy working committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Grants Working Group member
California Institute for Regenerative Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wayne Clark, MD
Oregon Health & Science University
Eric Simpson, MD
Oregon Health & Science University
Helmi Lutsep, MD
Oregon Health & Science University
Eric Suhler, MD
Oregon Health & Science University
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center